Ezra Eddy Wyssam Cohen

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. pmc A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 69:65-74. 2009
  2. doi request reprint Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Head Neck 31:1013-21. 2009
  3. pmc Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy
    Ezra E W Cohen
    Department of Medicine, University of Chicago, United States University of Chicago Comprehensive Cancer Center, United States Electronic address
    Oral Oncol 49:1025-31. 2013
  4. doi request reprint Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients
    Ezra E W Cohen
    Departments of Medicine, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 18:4785-93. 2012
  5. pmc Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies
    Aaron W Pederson
    Department of Radiation Oncology, Memorial University Medical Center, 4700 Waters Avenue, Savannah, GA 31404, USA
    Head Neck Oncol 3:31. 2011
  6. ncbi request reprint Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    J Clin Oncol 24:2659-65. 2006
  7. ncbi request reprint High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA
    J Clin Oncol 24:3438-44. 2006
  8. ncbi request reprint Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Int J Radiat Oncol Biol Phys 67:678-84. 2007
  9. ncbi request reprint A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 13:4317-9. 2007
  10. pmc Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer
    Ezra E W Cohen
    Department of Medicine, University of Chicago, Chicago, IL, USA
    J Clin Oncol 28:3336-43. 2010

Research Grants

Detail Information

Publications49

  1. pmc A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 69:65-74. 2009
    ....
  2. doi request reprint Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Head Neck 31:1013-21. 2009
    ..Patients with T4 oral cavity (OC) tumors are often treated with surgery followed by adjuvant chemoradiotherapy (CRT)...
  3. pmc Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy
    Ezra E W Cohen
    Department of Medicine, University of Chicago, United States University of Chicago Comprehensive Cancer Center, United States Electronic address
    Oral Oncol 49:1025-31. 2013
    ..This will allow identification of patients that will require more intensive supportive care using thermal imaging technology...
  4. doi request reprint Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients
    Ezra E W Cohen
    Departments of Medicine, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 18:4785-93. 2012
    ..Nevertheless, sirolimus is readily available, has been well studied in organ transplant patients, and shows efficacy in several preclinical cancer models...
  5. pmc Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies
    Aaron W Pederson
    Department of Radiation Oncology, Memorial University Medical Center, 4700 Waters Avenue, Savannah, GA 31404, USA
    Head Neck Oncol 3:31. 2011
    ..To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy...
  6. ncbi request reprint Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    J Clin Oncol 24:2659-65. 2006
    ..This article will review the progress in utilization of EGFR inhibitors in R/M SCCHN...
  7. ncbi request reprint High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA
    J Clin Oncol 24:3438-44. 2006
    ..This study was undertaken to assess whether shortening treatment duration with hyperfractionated RT would be feasible and improve locoregional control, organ preservation, and progression-free survival...
  8. ncbi request reprint Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Int J Radiat Oncol Biol Phys 67:678-84. 2007
    ..The hypoxic cell sensitizer, tirapazamine (TPZ), has demonstrated promising results in first-line therapy for HNC. This phase I trial was designed to test the feasibility of giving TPZ in the re-RT setting...
  9. ncbi request reprint A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 13:4317-9. 2007
  10. pmc Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer
    Ezra E W Cohen
    Department of Medicine, University of Chicago, Chicago, IL, USA
    J Clin Oncol 28:3336-43. 2010
    ....
  11. doi request reprint Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago Division of Biological Sciences, 5801 S Ellis, Chicago, IL 60637, USA
    J Clin Oncol 26:4708-13. 2008
    ..This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer...
  12. doi request reprint A phase I study of sirolimus and bevacizumab in patients with advanced malignancies
    E E W Cohen
    Section of Hematology and Oncology, Department of Medicine, Comprehensive Cancer Center, Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL, USA
    Eur J Cancer 47:1484-9. 2011
    ..We performed a single institution, phase I study of sirolimus and bevacizumab, in order to determine the dose limiting toxicity (DLT) and recommended phase II doses...
  13. ncbi request reprint Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Clin Cancer Res 11:8418-24. 2005
    ..This study evaluated the efficacy and toxicity of 250 mg daily gefitinib in patients with recurrent and/or metastatic SCCHN...
  14. pmc Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck
    Ezra Eddy Wyssam Cohen
    University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, United States
    Oral Oncol 45:e155-60. 2009
    ..EGFR mechanistic toxicities that develop during therapy are also highly associated with benefit and suggest a relationship between drug exposure and outcome...
  15. ncbi request reprint Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
    J Clin Oncol 21:1980-7. 2003
    ..ZD1839 is an orally active, selective EGFR tyrosine kinase inhibitor. This phase II study sought to explore the activity, toxicity, and pharmacodynamics of ZD1839 in SCCHN...
  16. ncbi request reprint Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Room MC2115, Chicago, IL 60637 1470, USA
    Hematol Oncol Clin North Am 18:81-90. 2004
    ..The latter platform, however, should be undertaken with caution, ideally in a clinical trial setting...
  17. ncbi request reprint Novel therapeutic targets in squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637 1470, USA
    Semin Oncol 31:755-68. 2004
    ..These systems and specific protein targets will be reviewed in detail with emphasis on promising preclinical and early clinical evidence of activity...
  18. ncbi request reprint The expanding role of systemic therapy in head and neck cancer
    Ezra E W Cohen
    Department of Medicine, Section of Hematology Oncology, University of Chicago Cancer Research Center, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
    J Clin Oncol 22:1743-52. 2004
    ..This review will focus on current therapy for locally advanced, recurrent, and metastatic SCCHN and discuss controversies and directions for future research...
  19. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
    ....
  20. doi request reprint Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer
    Tanguy Y Seiwert
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    J Clin Oncol 26:1732-41. 2008
    ....
  21. doi request reprint Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin
    Jing Liu
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Head Neck 33:1774-82. 2011
    ..Enzastaurin is an AGC kinase inhibitor with nanomolar inhibitory concentrations for Akt and protein kinase C (PKC). Moreover, Akt and PKC inhibitors have demonstrated efficacy in SCCHN...
  22. ncbi request reprint Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase
    Ezra Eddy Wyssam Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Res 66:6296-303. 2006
    ....
  23. doi request reprint Mechanisms of resistance to EGFR inhibitors in head and neck cancer
    Jonathan B Cooper
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Head Neck 31:1086-94. 2009
    ..Published studies and abstracts reveal that there are likely several mechanisms underlying resistance, suggesting that different strategies will be required to improve efficacy of EGFR inhibitors in HNSCC...
  24. pmc Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA University of Chicago Cancer Research Center, Chicago, IL, USA
    Lancet Oncol 10:247-57. 2009
    ..In this multi-institutional phase I/II study we combined an EGFR inhibitor, erlotinib, with an anti-VEGF antibody, bevacizumab...
  25. doi request reprint A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
    Ann M Mauer
    University of Chicago Medical Center, Chicago, Illinois 60637, USA
    J Thorac Oncol 3:631-6. 2008
    ..To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC)...
  26. pmc Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context
    Wen Liang Kuo
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Mol Cancer Ther 9:2814-24. 2010
    ....
  27. doi request reprint Phase II study of sunitinib malate in head and neck squamous cell carcinoma
    Nicholas W Choong
    Section of Hematology Oncology and Phase II Network, University of Chicago Medical Center, S Maryland Avenue, Chicago, IL 60637, USA
    Invest New Drugs 28:677-83. 2010
    ..Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor of RET, VEGFR, PDGFR, and c-KIT. We conducted a phase II trial to evaluate the tolerability and efficacy of sunitinib in metastatic and/or recurrent SCCHN patients...
  28. ncbi request reprint Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors
    Syed M Ahmed
    Section of Hematology Oncology, Department of Medicine, The University of Chicago Medical Center, The Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Cancer Drug Targets 7:666-73. 2007
    ..This article reviews the advances that have made in treating refractory and metastatic disease, with particular focus on the challenges that are faced in successfully translating EGFR inhibition as a paradigm of tumor treatment in SCCHN...
  29. ncbi request reprint A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer
    Tanguy Y Seiwert
    Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Cancer Invest 25:435-44. 2007
    ..Median overall (OS) has not been reached and 2-year OS is 80.7 percent. The recommended Phase II dose of docetaxel with FHX CRT is 25 mg/m(2) and 35 mg/m(2) in combination with carboplatin induction (AUC = 6)...
  30. ncbi request reprint Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR
    Ezra E W Cohen
    Department of Medicine, University of Chicago, Illinois, USA
    Clin Cancer Res 11:8105-8. 2005
    ..The objective of this study was to determine if such mutations, or recently reported mutations in ERBB2, also underlie EGFR-TKI responsiveness in SCCHN patients...
  31. doi request reprint Chemoradiation for patients with advanced oral cavity cancer
    Kerstin M Stenson
    Section of Otolaryngology Head and Neck Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA
    Laryngoscope 120:93-9. 2010
    ..The purpose of this study was to analyze survival, swallowing function, and incidence of osteoradionecrosis (ORN) of patients with stage III/IV OCC who have undergone primary concomitant chemoradiotherapy (CRT)...
  32. doi request reprint The next phase of chemoprevention research
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago MC2115, Chicago, IL 60637, USA
    Cancer Prev Res (Phila) 4:293-5. 2011
    ..Indeed, aspects of the phase 0 design lend themselves well to chemoprevention research, suggesting that this approach will become more common in the near future...
  33. pmc The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
    Tanguy Y Seiwert
    Section of Hematology Oncology, Department of Medicine and University of Chicago Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 69:3021-31. 2009
    ..MET inhibition abrogated MET functions, including proliferation, migration/motility, and angiogenesis. MET is a promising, novel target for HNSCC and combination approaches with cisplatin or EGFR inhibitors should be explored...
  34. ncbi request reprint An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia
    Charles M Rudin
    Medical Center, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    J Clin Oncol 21:4546-52. 2003
    ..The current study sought to establish the feasibility and activity of ONYX-015 administered topically as a mouthwash to patients with clinically apparent and histologically dysplastic lesions of the oral mucosa...
  35. ncbi request reprint Epidermal growth factor receptor directed therapy in head and neck cancer
    Nicholas W Choong
    University of Chicago Medical Center, MC 2115, 5841, S Maryland Avenue, Chicago, IL 60615, USA
    Crit Rev Oncol Hematol 57:25-43. 2006
    ..With the foundation for the use of EGFR inhibitors laid in these studies, future studies will need to optimize the delivery of these agents in combination with conventional therapies...
  36. ncbi request reprint Planned post-chemoradiation neck dissection: significance of radiation dose
    Kerstin M Stenson
    Department of Surgery, Section of Otolaryngology Head and Neck Surgery, University of Chicago, Illinois 60637, USA
    Laryngoscope 116:33-6. 2006
    ..We report the pathologic data on patients undergoing neck dissection (ND) after induction chemotherapy followed by concomitant chemoradiotherapy (IC-CRT) in three similar protocols utilizing decreasing doses of radiation therapy...
  37. ncbi request reprint Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment
    Neil Mehta
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Int J Oncol 25:1677-83. 2004
    ..Our data support the feasibility of a clinical trial that incorporates local therapies to sterilize metastases in patients with NSCLC...
  38. ncbi request reprint Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study
    Philip C Hoffman
    Department of Medicine, The University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Lung Cancer 38:65-71. 2002
    ..5 months. We conclude that the combination of carboplatin, vinorelbine, and radiotherapy is feasible at these doses. It may be a useful alternative for patients not able to tolerate cisplatin-based therapy...
  39. doi request reprint Targeting angiogenesis in head and neck cancer
    Tanguy Y Seiwert
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, Chicago, IL 60637 1470, USA
    Semin Oncol 35:274-85. 2008
    ..With the intense research effort preclinically and clinically, and some encouraging early results, anti-angiogenic therapies and biomarkers appear to be poised to play an important role in the treatment of HNC in the near future...
  40. doi request reprint Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model
    Urszula Dougherty
    Department of Medicine, University of Chicago Hospitals and Clinics, Chicago, IL 60637, USA
    Clin Cancer Res 14:2253-62. 2008
    ..Recent studies indicate that flat dysplastic ACF with increased beta-catenin are tumor precursors in this model. We asked, therefore, if EGFR signals are required for flat dysplastic ACF development and cancer progression...
  41. pmc New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors
    Lucy F Chen
    University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 16:2489-95. 2010
    ....
  42. doi request reprint Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents
    Masha Kocherginsky
    Department of Health Studies, University of Chicago, Chicago, Illinois 60637, USA
    J Biopharm Stat 19:524-9. 2009
    ..An early stopping rule for lack of efficacy is incorporated. The method is illustrated by the design of a Phase II clinical trial in head and neck cancer...
  43. doi request reprint Free-flap reconstruction in the doubly irradiated patient population
    Alvin B Cohn
    Sections of Plastic and Reconstructive Surgery and Otolaryngology, Head and Neck Surgery, Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Ill, USA
    Plast Reconstr Surg 122:125-32. 2008
    ..After reirradiation, these patients commonly present with extensive tissue loss, nonhealing wounds, contractures, and fistulas, and free-flap reconstruction is often necessary to correct the perils of oncologic treatment...
  44. doi request reprint Introduction: head and neck cancer
    Everett E Vokes
    University of Chicago, Chicago, IL, USA
    Semin Oncol 35:196-7. 2008
  45. ncbi request reprint Searching for a standard
    Ezra E W Cohen
    J Clin Oncol 20:359-61. 2002
  46. ncbi request reprint A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores
    Susan Yount
    Center on Outcomes, Research and Education CORE, Evanston Northwestern Healthcare, Evanston, IL 60201, USA
    Qual Life Res 16:1615-26. 2007
    ..To evaluate the impact of administration context (embedded versus stand-alone) on the reliability and validity of the FACT Head and Neck Symptom Index (FHNSI)...
  47. doi request reprint mTOR: the mammalian target of replication
    Ezra E W Cohen
    J Clin Oncol 26:348-9. 2008
  48. ncbi request reprint Forthcoming receptor tyrosine kinase inhibitors
    Nicholas W Choong
    Expert Opin Ther Targets 10:793-7. 2006
    ..This is an exciting time in cancer therapeutics, highlighted by the advent of effective targeted therapy with receptor tyrosine kinase inhibitors...
  49. ncbi request reprint Iodine-refractory thyroid carcinoma
    Apar Kishor Ganti
    Division of Oncology Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Rev Recent Clin Trials 1:133-41. 2006
    ..Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodine-refractory thyroid carcinoma and current novel therapeutic approaches will be emphasized...

Research Grants3

  1. Rapamycin as an Antineoplastic Agent
    Ezra Cohen; Fiscal Year: 2006
    ..At the conclusion of the trial RAPA toxicity and effect on p-S6K will be defined over a range of doses as well as the MTD for use in future studies that will develop this agent. ..
  2. Functional Infrared Imaging Predicts Radiation Mucositis
    Ezra Cohen; Fiscal Year: 2007
    ..Such a tool would have wide applicability in this patient population and would have tremendous impact on their treatment. ..